Notice of Extraordinary General Meeting of Implantica AG

The shareholders of Implantica AG (publ), reg. no. FL-0002.629.889-3, are hereby given notice of the extraordinary general meeting on Friday, September 17, 2021, at 14:30.

To protect the health and safety of all participants in connection with the spread of COVID-19, the extraordinary general meeting on Friday, September 17, 2021, will be reduced to the legally required minimum. The EGM will take place without the personal participation of shareholders and only the statutorily required people will attend the meeting, which will include representation from the Amt für Justiz in Liechtenstein. The meeting process will include control that the meeting was duly convened and control of the shareholder and voting lists.

Depository receipt holders will be able to vote by submitting their voting form to Pareto Securities AB (the “Custodian”), who will forward the votes to the independent proxy (Article 11 para. 4 lit. b of the Act of 8 April 2020 on accompanying measures in judicial and administrative procedures in the context of Covid-19, LGBl 2020/136).

Depository receipt holders have the opportunity to submit questions in respect of the EGM by sending them to investorrelations@implantica.com before September 17, 2021.

Right to participate

Those wishing to participate in the meeting, through postal voting, must

• Be entered as depository receipt holders in the Swedish Depository Receipt register kept by the Swedish central securities depository Euroclear Sweden on Monday, September 6, 2021 and
• Cast their vote no later than Thursday, September 9, 2021, in accordance with the instructions on the Postal Voting Form, see appendix 1, so that the voting form is received by Pareto Securities AB no later than that day.

Holders of depository receipts who hold their receipts through nominees (Sw. förvaltare) must request a temporary registration of the voting rights in order to be able to participate at the Meeting. Holders of depository receipts who want to obtain such registration must contact the nominee regarding this in advance of September 6, 2021.

Agenda items

The following agenda items are scheduled for the Extraordinary General Meeting (“EGM”):

1. Approval of the proposed merger plan for the merger of Implantica MediSwiss AG as the transferring company into Implantica AG as the acquiring company (downstream merger)

The following documents will be available for review by the shareholders at the company's headquarters, Landstrasse 1, Vaduz and on the company's website www.implantica.com:

-      the merger plan

-      the annual accounts and the annual reports of the merging companies Implantica AG and Implantica MediSwiss AG for the last three financial years

-      the half-year financial reports for 2021 ending June 30, 2021 of the merging companies Implantica AG (unaudited) and Implantica MediSwiss AG (audited)

-      the merger report by the board of directors

-      the expert report of Deloitte.

Proposal of the Board of Directors:

The Board of Directors proposes to approve the merger plan dated August 17, 2021, between Implantica MediSwiss AG and Implantica AG, which is included as an attachment (appendix 2).

2. Resolution on amendment of Article 4 para. 1 of the Articles of Association and confirmation of the Board’s acceptance of a contribution from the main shareholder of EUR 117 million to the reserves (without monetary compensation)

Resolve on an amendment of the Articles of Association to perform a stock split in the class B shares, reflecting the status of the transferring company, Implantica MediSwiss AG, subject to the registration of the merger between Implantica MediSwiss AG and Implantica AG in the Liechtenstein commercial register as a condition precedent, and thereby also confirming the Board’s decision to accept a contribution into the reserves (subject to the split as a condition subsequent) of 51% of the shares in MedicalTree Swiss AG valued at EUR 117 million by one of the big four auditors.

Proposal of the Board of Directors:

Art. 4 para. 1: The share capital of the Company is CHF 138’723’074, fully paid-in and divided into

58’111’537 registered shares (Class A), each with a nominal value of CHF 2 and

56’250’000 1’125’000’000 registered shares (Class B), each with a nominal value of CHF 0.40 CHF 0.02.

Art. 4 Abschnitt 1: Das Aktienkapital der Gesellschaft beträgt CHF 138‘723‘074, ist voll liberiert und eingeteilt in

58‘111‘537 auf den Namen lautende Aktien (Class A) mit einem Nennwert von CHF 2 je Aktie und

56‘250‘000 1‘125‘000‘000 auf den Namen lautende Aktien (Class B) mit einem Nennwert von CHF 0.40 CHF 0.02 je Aktie.

3. Resolution on amendment of Article 11 para. 3 of the Articles of Association

Resolve on an amendment of the Articles of Association for the Board of Directors to set a record date not more than two weeks before the date of the General Meeting of Shareholders in order to allow the necessary time for the list of depositary receipt holders to be compiled by Euroclear, sent to the Custodian and thereafter the local independent proxy.

Proposal of the Board of Directors:

Art. 11 para. 3: If the company is listed on a regulated market or stock exchange or at the initiative of the company its shares are traded at any other marketplace, the Board of Directors is entitled to set a record date in the invitation to the General Meeting of Shareholders, which may not be more than one week two weeks before the date of the General Meeting of Shareholders. If a record date is set, only those persons who can prove that they hold shares in the Company on the record date are entitled to attend the General Meeting. The Board of Directors shall determine the procedure for providing such evidence and announce it in the invitation to the General Meeting.

Art. 11 Abschnitt 3: Ist die Gesellschaft an einer Börse oder einem regulierten Markt kotiert oder auf Anlass der Gesellschaft an einem sonstigen Handelsplatz ihre Aktien gehandelt werden, ist der Verwaltungsrat berechtigt, in der Einladung zur Generalversammlung einen Nachweisstichtag festzulegen, der nicht mehr als eine Woche zwei Wochen vor dem Datum der Generalversammlung liegen darf. Wird ein Nachweisstichtag festgelegt, sind nur diejenigen Personen zur Teilnahme an der Generalversammlung berechtigt, die nachweisen, dass sie zum Nachweisstichtag Aktien der Gesellschaft halten. Der Verwaltungsrat legt das Verfahren des Nachweises fest und gibt es in der Einladung zur Generalversammlung bekannt.

Voting

Depository receipt holders are invited to send their votes to the Custodian as outlined in the Postal Voting Form (appendix 1). The Custodian will forward the votes for representation to the local independent proxy, Mr. Philipp Wanger, Attorney-at-law.

Minutes

The minutes of the extraordinary general meeting will be available for review from the evening of October 1, 2021, at the latest at the company’s headquarters, Landstrasse 1, Vaduz and on the company’s website www.implantica.com.

Implantica AG

The Board of Directors

August 17, 2021
 

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.seThe information was sent for publication, through the agency of the contact person set out above, on August 17, 2021 at 17:40 CEST.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.